Illustration: Axios Visuals
CERo Therapeutics (Nasdaq: CERO), a T cell therapy biotech, is open to licensing deals or a sale as it awaits data on its lead asset, CEO Chris Ehrlich tells Axios Pro.
Why it matters: Cell therapy companies have been catching the eye of Big Pharma.
